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Endothelin receptor antagonists in clinical research— Lessons learned
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Endothelin receptor antagonists are approved for the treatment
of pulmonary hypertension. The efforts to approve this class of drugs
for renal indications, however, failed so far. Preclinical studies were
promising. Transgenic overexpression of ET-1 or ET-2 in rodents causes
chronic renal failure in a blood pressure independent manner. Blocking
in particular the ETA receptor was effective in the treatment of rodent
models of renal failure such as rats with 5/6 nephrectomy, L-NAME
induced renal failure and diabetic nephropathy. On the other hand,
various animal studies indicate that blocking the renal tubular ETA
and ETB receptormay causewater and salt retention partially mediated
via the epithelial sodium transporter (ENaC) in tubular cells. Endo-
thelin receptor antagonists were successfully tested clinically in renal
indications in phase 2 trials for the treatment of diabetic nephropathy.
They showed efﬁcacy in terms of reducing albumin excretion in patients
with diabetic nephropathy on top of guideline based background
therapy (angiotensin II receptor blockade). However, these promising
results could not be translated to successful phase III trials so far.
The spectrum of serious adverse events was similar to other phase III
trials using endothelin receptor antagonists. We will discuss potential
underlying reasons for these failures and what could be done in the
future. The lessons learned in renal indications are also important
for other potential indications of endothelin receptor antagonists like
cancer and heart failure.
doi:10.1016/j.lfs.2013.12.224
Endothelin receptor antagonism versus combined ECE/NEP
inhibition in patients with type 2 diabetes and nephropathy
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Endothelin receptor antagonists have been used in clinical trials to
test their renoprotection properties in patients with type 2 diabetes who
do not invariably respond to angiotensin II blockers. Thus, combined
treatment with ET-1 antagonists on top of angiotensin II blockers could
represent an effective tool to reduce blood pressure and ameliorating
renal function. Here we tested the effect of combined treatment with
daglutril, a combined endothelin-converting-enzyme and neutral endo-
peptidase (MME) inhibitor on top of losartan (100 mg/day) in patients
with type 2 diabetes. The randomised, crossover trial was held in two
hospitals in Italy. Eligibility criteria were: age 18 years or older, urinary
albumin excretion 20–999 μg/min, systolic blood pressure (BP) less
than 140 mmHg, and diastolic BP less than 90 mmHg. Patients were
randomly assigned (1:1) with a computer-generated randomized
sequence to receive either daglutril (300 mg/day) then placebo for
8 weeks each or vice versa, with a 4-weekwashout period. The primary
endpoint was 24-h urinary albumin excretion in the intention-to-treat
population. Secondary endpoints were median ofﬁce and ambulatory
(24 h, daytime, and night-time) BP, renal haemodynamics and sieving
function, and metabolic and laboratory test results. This study is
registered with ClinicalTrials.gov, number NCT00160225. 58 patients
were screened, ofwhom45were enrolled (22 assigned to daglutril then
placebo, 23 to placebo then daglutril) and42 (20 vs 22)were included in
the primary analysis. Daglutril did not signiﬁcantly affect 24-h urinary
albumin excretion compared with placebo (p = 0.559). 34 patients had
complete 24-h BP readings; compared with placebo, daglutril signiﬁ-
cantly reduced ambulatory systolic (p = 0.0013), diastolic (p = 0.015),
pulse (p= 0.019), and mean (p= 0.003) BP, as well as all night-time
BP readings and daytime systolic, pulse, and mean BP, but not diastolic
BP. Compared with placebo, daglutril also signiﬁcantly reduced ofﬁce
systolic BP (p = 0.028), but not diastolic, pulse, or mean BP, and in-
crease big endothelin serum concentration. Three patients taking
placebo and six patients taking daglutril had mild treatment-related
adverse events — the most common was facial or peripheral oedema
(in four patients taking daglutril).Our data suggest that daglutril im-
proved control of BP in hypertensive patients with type 2 diabetes and
nephropathy particularly as for systolic hypertension, that in patients
with diabetes and renal involvement is often resistant to treatment. The
treatment effect of daglutril was larger during night time, which is of
major clinical relevance, since night time hypertension is a strong
cardiovascular risk factor in this patient population. We also found that
daglutril on top of full dose losartan had a very good safety proﬁle.
doi:10.1016/j.lfs.2013.12.225
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Introduction and Aims: Patients with type 2 diabetes and albumin-
uria have high cardiorenal morbidity and mortality. We evaluated
whether atrasentan, a selective endothelin receptor A antagonist, could
reduce albuminuria in use with renin angiotensin system inhibitors
(RASi). Methods: 211 subjects with type 2 diabetes, macroalbuminuria,
0024-3205/© 2013 The Authors. Published by Elsevier Inc.
Life Sciences 93 (2013) e58–e59
Contents lists available at ScienceDirect
Life Sciences
j ourna l homepage: www.e lsev ie r.com/ locate / l i fesc ie
Open access under CC BY-NC-ND license.
and eGFR between 30 and 75 ml/min/1.73 m2, were enrolled in 2
parallel, multinational, double-blind, randomized, placebo-controlled
studies. Subjects were randomized to atrasentan 0.75, 1.25 mg QD or
placebo for 12 wks after a run-in period that maximized the RASi dose.
Results: Mean UACR values (placebo, 0.75, 1.25 mg) at baseline: 671,
878, and 826 mg/g; wk 2: 696 (NS), 573 and 515 mg/g, (p b 0.001);
and wk 12: 797 (NS), 521 and 470 mg/g (p b 0.001). More than 30%
albuminuria reductionwas observed in 51 and 55% of subjects receiving
atrasentan. eGFR (49 ± 13, 48 ± 15, and 51 ± 14ml/min at baseline)
did not change signiﬁcantly compared with placebo. Mean LDL-C
changed by +2± 3,−13 ± 2 and−13 ± 2mg/dl (p b 0.001). Similar
changes were observed in triglyceride levels. No differenceswere noted
in the rate of peripheral edema or heart failure. At week 2, body weight
increased (0.7 and 1.2 kg), but weight was not signiﬁcantly different
from baseline at week 12 for the 0.75 mg group. After stopping
atrasentan for 30 days, all of the parameters described above returned
to pretreatment values. Conclusions: Chronic administration of atra-
sentan reduces albuminuria in patients who are receiving maximum
RAS inhibition without incurring volume-related adverse events.
doi:10.1016/j.lfs.2013.12.226
A placebo-controlled study of ambrisentan in subjects with
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Rationale: Idiopathic pulmonary ﬁbrosis (IPF) is characterized by
the formation and proliferation of ﬁbroblast foci. Endothelin-1 induces
lung ﬁbroblast proliferation and contractile activity via the endothelin A
(ETA) receptor. Data from preclinical models suggests that endothelin
blockade can attenuate pulmonary ﬁbrosis. This study tested the
hypothesis that ambrisentan, an endothelin type A receptor speciﬁc
antagonist approved for the treatment of pulmonary arterial hyperten-
sion, reduces disease progression in subjectswith idiopathic pulmonary
ﬁbrosis (IPF). Methods: This was a randomized (2:1), double-blind,
placebo-controlled, event-driven trial enrolling subjects with IPF.
Randomization was stratiﬁed by the presence of pulmonary hyperten-
sion at baseline, determined by a right heart catheterization, and IPF
diagnosis by surgical lung biopsy. The primary endpointwas time to IPF
disease progression, deﬁned as all-cause mortality, adjudicated respi-
ratory hospitalization, or a categorical decrease in lung function deﬁned
as a 10% decrease in forced vital capacity [FVC]with a 5% decrease in the
diffusion capacity for carbon monoxide [DLCO] or a 15 % decrease in
DLCO with a 5% decrease in FVC. Results: At 75% (492 subjects) of the
intended total enrolment and after a mean exposure of 34 weeks to the
study drug, the Data Safety Monitoring Board terminated the study due
to a low likelihood of demonstrating efﬁcacy. From 136 clinical sites,
329 and 163 subjects were randomized to receive ambrisentan or
placebo respectively. At baseline, 36 (11%) and 18 (11%) subjects had
pulmonary hypertension (PH) with a mPAP N 25mmHg and wedge
pressure b 15 mmHg in the ambrisentan and placebo groups respec-
tively. Ambrisentan treated subjects hadmore primary endpoint events
(90 [27.4%] versus 28 [17.2%]), and a 1.74 fold increase in risk of
meeting the primary endpoint (95% conﬁdence interval [CI] 1.14–2.66,
p = 0.010). Evaluation of the primary endpoint components indicated
that the number of deaths (hazard ratio [HR] 2.08, 95% CI 0.75–5.76,
p = 0.100) and subjects with a categorical decrease in lung function
(HR 1.53, 95% CI 0.84–2.78, p = 0.109)was not statistically signiﬁcantly
different between the groups. However, ambrisentan treated subjects
had more respiratory hospitalizations (44 [13%] versus 9 [6%]), and a
2.59 fold increase in risk of experiencing a respiratory hospitalization
(95% CI 1.14–5.89, p = 0.007). Stepwise Cox multivariate analysis
revealed that after adjustment for baseline IPF severity, the risk for
primary events was reduced and the p-value was N0.1 (HR 1.42, 95% CI
0.85–2.05, p = 0.108). Although the risk for respiratory hospitalization
was also reduced, the p-value remained b0.05 (HR 2.11, 95% CI 1.03–
4.33, p = 0.042). The presence of PH at baseline did not affect these
point estimates signiﬁcantly. The secondary endpoints (FVC, DLCO,
6MWD, TDI and QoL) at 48 weeks and the incidence of liver toxicity
were not statistically signiﬁcantly different between the groups.
Conclusions: Ambrisentan was ineffective in reducing disease progres-
sion in IPF and was associated with an increased risk of respiratory
hospitalizations. While there is no evidence of treatment beneﬁt,
all analyses need to be interpreted cautiously as ARTEMIS-IPF was
terminated early for lack of efﬁcacy.
This study was funded by Gilead Sciences, Inc.
doi:10.1016/j.lfs.2013.12.227
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markers for remodeling and neutrophil activation in patients
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Background: Endothelin (ET) is a pro-ﬁbrotic vasoconstrictor and a
mediator of microvascular dysfunction and cardiac remodeling. Animal
studies investigating ET receptor blockade in acutemyocardial infarction
led to conﬂicting results regarding ventricular remodeling. In-vitro, ET-A
receptor blockade decreases neutrophil activation. Methods: Patients
with posterior-wall STE-ACS were treated with BQ-123, a selective
ET-A receptor antagonist as previously described (n= 54). Peripheral
blood samples were drawn at baseline, 24 h and 30 days after PCI.
Myeloperoxidase (MPO), matrix metalloproteinase 9 (MMP-9) and the
procollagen III N-terminal propeptide (PIIINP),weremeasured in plasma
using commercially available assays. Results: Patients randomized to
BQ-123 demonstrated a greater reduction ofMPO levels frombaseline to
24 h compared to placebo-treated patients ((177 ng/mL reduction for
BQ-123 versus 108 ng/mL for placebo, p = 0.006), Fig. 1a). In addition,
we observed a signiﬁcantly greater reduction ofMMP-9 levels in patients
treated with study drug (568 ng/mL versus 117 ng/mL, p = 0.018,
Fig. 1b).There was no signiﬁcant difference in PIIINP values. Conclusion:
Short-term administration of BQ-123 reduces MPO and MMP-9 plasma
levels in patients with STE-ACS. In trials with larger patient numbers this
may translate into improved ventricular remodeling at six months.
doi:10.1016/j.lfs.2013.12.228
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